Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events
Alessio Cortellini, Melissa Bersanelli, Daniele Santini, Sebastiano Buti, Marcello Tiseo, Katia Cannita, Fabiana Perrone, Raffaele Giusti, Michele De Tursi, Federica Zoratto, Riccardo Marconcini, Marco Russano, Tea Zeppola, Cecilia Anesi, Marco Filetti, Paolo Marchetti, Andrea Botticelli, Alain Gelibter, Federica De Galitiis, Maria Giuseppa Vitale, Francesca Rastelli, Marianna Tudini, Rosa Rita Silva, Francesco Atzori, Rita Chiari, Biagio Ricciuti, Andrea De Giglio, Maria Rita Migliorino, Domenico Mallardo, Vito Vanella, Claudia Mosillo, Sergio Bracarda, Silvia Rinaldi, Rossana Berardi, Clara Natoli, Corrado Ficorella, Giampiero Porzio, Paolo A. Ascierto
Topics & Concepts
MedicineUnderweightOverweightInternal medicineBody mass indexDiscontinuationOdds ratioAdverse effectCancerRenal cell carcinomaUnivariate analysisLung cancerOncologyMultivariate analysisCancer Risks and FactorsCancer Immunotherapy and BiomarkersMultiple and Secondary Primary Cancers